Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Indole-3-carbinol · 1 trial · 1 indication
Change in average daily VAS (in mm) endometriosis-related pelvic pain score (cyclic and non-cyclic, combined) during Treatment Period 6 (assessed at Visit 7) in comparison to Screening Cycle as reported in the participant's diary.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Participants receive Indinol Forto 200 mg capsules orally twice a day during 24 weeks |
| Arm 2 | ACTIVE_COMPARATOR | Participants receive Visanne 2 mg tablets orally once a day during 24 weeks |
| Name | Type | Description |
|---|---|---|
| Indole-3-carbinol | DRUG | Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks |
| Dienogest | DRUG | Visanne (dienogest) 2 mg tablets orally once a day during 24 weeks |
Inclusion Criteria: 1. The participant provides written informed consent for participation in the study in accordance with current legislation. 2. Female participants in reproductive/premenopausal period from 18 to 45 years old inclusively (at the moment of signing informed consent). 3. Participant...